Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: Cancer J Clin 68 394-424

[2] Ferlay J(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921

[3] Soerjomataram I(2008)Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol: Off J Am Soc Clin Oncol 26 3496-3502

[4] Siegel RL(2014)Outcomes in operative management of pancreatic cancer J Surg Oncol 110 592-598

[5] Torre LA(2013)Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines Pancreas 42 1004-1010

[6] Jemal A(2018)Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Cancer Chemother Pharmacol 81 815-821

[7] Rahib L(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet (London, England) 388 248-257

[8] Smith BD(2009)Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival Pancreas 38 605-612

[9] Aizenberg R(2020)Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma Virchows Archiv: Int J Pathol 476 561-568

[10] Rosenzweig AB(2018)Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system Histopathology 73 137-146

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: Cancer J Clin 68 394-424

[2] Ferlay J(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921

[3] Soerjomataram I(2008)Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head J Clin Oncol: Off J Am Soc Clin Oncol 26 3496-3502

[4] Siegel RL(2014)Outcomes in operative management of pancreatic cancer J Surg Oncol 110 592-598

[5] Torre LA(2013)Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines Pancreas 42 1004-1010

[6] Jemal A(2018)Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer Cancer Chemother Pharmacol 81 815-821

[7] Rahib L(2016)Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Lancet (London, England) 388 248-257

[8] Smith BD(2009)Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival Pancreas 38 605-612

[9] Aizenberg R(2020)Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma Virchows Archiv: Int J Pathol 476 561-568

[10] Rosenzweig AB(2018)Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system Histopathology 73 137-146